Platelet-mediated tumor metastasis mechanism and the role of cell adhesion molecules

Liu, Yitian; Zhang, Yuan; Ding, Yong; Zhuang, Ran

doi:10.1016/j.critrevonc.2021.103502

Cited by 55 publications

(36 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platelets also activate endothelial cells, recruit immunocytes, and facilitate tumor cell spread ( 58 ). Platelets enhance tumor growth, invasion, and metastasis by promoting proliferation, antiapoptosis, pro-angiogenic signals, and the invasive tumor cell epithelial-mesenchymal transition (EMT) phenotype ( 59 – 62 ). Activated platelets also secrete transforming growth factor β (TGF-β) into the tumor microenvironment (TME), suppress tumor immunity, and favor cancer cell evasion of the host immune system ( 63 ).…”

Section: Discussionmentioning

confidence: 99%

Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis

Liu

Shimada

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Atherosclerosis (AS) and cancers are major global causes of mortality and morbidity. They also share common modifiable pathogenesis risk factors. As the same strategies used to predict AS could also detect certain cancers, we sought novel serum antibody biomarkers of cancers in atherosclerotic sera sampled by liquid biopsy. Using serological antigen identification by cDNA expression cloning (SEREX) and western blot, we screened and detected the antigens BRCA1-Associated ATM Activator 1 (BRAT1) and WD Repeat Domain 1 (WDR1) in the sera of patients with transient ischemic attacks (TIA). Amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) established the upregulation of serum BRAT1 antibody (BRAT1-Abs) and WDR1 antibody (WDR1-Abs) in patients with AS-related diseases compared with healthy subjects. ROC and Spearman’s correlation analyses showed that BRAT1-Abs and WDR1-Abs could detect AS-related diseases. Thus, serum BRAT1-Abs and WDR1-Abs are potential AS biomarkers. We used online databases and AlphaLISA detection to compare relative antigen and serum antibody expression and found high BRAT1 and BRAT1-Abs expression in patients with GI cancers. Significant increases (> 0.6) in the AUC for BRAT1-Ab vs. esophageal squamous cell carcinoma (ESCC), gastric cancer, and colorectal cancer suggested that BRAT1-Ab exhibited better predictive potential for GI cancers than WDR1-Ab. There was no significant difference in overall survival (OS) between BRAT1-Ab groups (P = 0.12). Nevertheless, a log-rank test disclosed that the highest serum BRAT1-Ab levels were associated with poor ESCC prognosis at 5–60 weeks post-surgery. We validated the foregoing conclusions by comparing serum BRAT1-Ab and WDR1-Ab levels based on the clinicopathological characteristics of the patients with ESCC. Multiple statistical approaches established a correlation between serum BRAT1-Ab levels and platelet counts. BRAT1-Ab upregulation may enable early detection of AS and GI cancers and facilitate the delay of disease progression. Thus, BRAT1-Ab is a potential antibody biomarker for the diagnosis of AS and GI cancers and strongly supports the routine clinical application of liquid biopsy in chronic disease detection and diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis

Liu

Shimada

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…CTCs activate platelets, and activated platelets accumulate and protect CTCs from NK cells and shear stress. Finally, CTC hypoxia tolerance is promoted by platelets, along with angiogenesis, EMT, extravasation, and ultimately metastasis [ 42 ]. Our results suggested an explanation for why HR group patients have a poorer outcome than LR patients, and the status of platelet activation may be a vital factor.…”

Section: Discussionmentioning

confidence: 99%

Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma

Wang

Chen

Xie

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Our study is aimed at constructing and validating a UPR-associated gene signature to predict HNSCC prognosis. We obtained 544 samples of RNA sequencing data and clinical characteristics from TCGA database and randomly grouped the samples into training and testing cohorts (1 : 1 ratio). After identifying 14 UPR-associated genes with LASSO and univariate Cox regression analysis, HNSCC samples were categorized into low-risk (LR) and high-risk (HR) subgroups depending on the risk score. Our analyses indicated that low-risk patients had a much better prognosis in the training and testing cohorts. To predict the HNSCC prognosis with the 14 UPR-associated gene signatures, we incorporated the UPR gene risk score, N stage, M stage, and age into a nomogram model. We further explored the sensitivity to anticancer drugs by using the IC50 analysis in two subgroups from the Cancer Genome Project database. The outcomes showed that the AKT inhibitor III and sorafenib were sensitive anticancer drugs in HR and LR patients, respectively. The immune cell infiltration analysis and GSEA provided strong evidence for elucidating the molecular mechanisms of UPR-associated genes affecting HNSCC. In conclusion, the UPR-associated gene risk score, N stage, M stage, and age can serve as a robust model for predicting prognosis and can improve decision-making at the individual patient level.

show abstract

“…This coating of CTCs by platelets can form intravascular micro-clots. All the factors conferred by the platelet by CTC provide firmness in cell proliferation and blood vessel formation in the tumor microenvironment [222].…”

Section: Contribution Of Platelets To Cancer Developmentmentioning

confidence: 99%

“…Once CTCs have managed to survive in the circulatory system with the help of platelets, they must fulfill the objective of creating metastatic foci, so they must leave the blood system and seed a second metastatic tumor [217][218][219][220][221][222][223]. Platelets stimulate extravasation by releasing ATP from their dense granules upon activation, which modulates endothelial junctions and the endothelial cytoskeleton to induce a breakdown of the endothelial barrier [223].…”

Section: Contribution Of Platelets To Cancer Developmentmentioning

confidence: 99%

Platelet Membrane: An Outstanding Factor in Cancer Metastasis

et al. 2022

View full text Add to dashboard Cite

In addition to being biological barriers where the internalization or release of biomolecules is decided, cell membranes are contact structures between the interior and exterior of the cell. Here, the processes of cell signaling mediated by receptors, ions, hormones, cytokines, enzymes, growth factors, extracellular matrix (ECM), and vesicles begin. They triggering several responses from the cell membrane that include rearranging its components according to the immediate needs of the cell, for example, in the membrane of platelets, the formation of filopodia and lamellipodia as a tissue repair response. In cancer, the cancer cells must adapt to the new tumor microenvironment (TME) and acquire capacities in the cell membrane to transform their shape, such as in the case of epithelial−mesenchymal transition (EMT) in the metastatic process. The cancer cells must also attract allies in this challenging process, such as platelets, fibroblasts associated with cancer (CAF), stromal cells, adipocytes, and the extracellular matrix itself, which limits tumor growth. The platelets are enucleated cells with fairly interesting growth factors, proangiogenic factors, cytokines, mRNA, and proteins, which support the development of a tumor microenvironment and support the metastatic process. This review will discuss the different actions that platelet membranes and cancer cell membranes carry out during their relationship in the tumor microenvironment and metastasis.

show abstract

Platelet-mediated tumor metastasis mechanism and the role of cell adhesion molecules

Cited by 55 publications

References 116 publications

Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis

Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis

Construction and Validation of a UPR-Associated Gene Prognostic Model for Head and Neck Squamous Cell Carcinoma

Platelet Membrane: An Outstanding Factor in Cancer Metastasis

Contact Info

Product

Resources

About